Additionally, the tumour mutational burden (TMB) derived from CGP panels, alongside certain genomic profiles combined with PD‐L1 immunohistochemistry (IHC), can better predict the efficacy of immunotherapy, potentially helping to avoid ineffective treatments associated with adverse outcomes. Here, CD274 is linked to neoplasm.